http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3651793-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5aafa2a59d0ceb267f3bdef79b1e4d2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-521 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 |
| filingDate | 2018-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ca6e8042252bc58690ba0cd0a327491 |
| publicationDate | 2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3651793-A1 |
| titleOfInvention | Composition, preparation method and evaluation of a complex immunogen named i-spga for production of immunological active proteins (iap) |
| abstract | The present invention relates to a composition and a process for preparing an immunogen called I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated by binary ethyleneimine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. Inoculation of hens with the immunogen I-spga results in hyperimmune eggs (Imunospga) which contain immunologically active proteins specific for the 18-26 antigens used for immunization. The immune response of chickens is specific for the antigens used by amplification of the antigenic signal by the SPGA immunopotentiator and because of a special immunization program that allows the immune system to act in a complex and intense manner.nThe I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, bacterial body components obtained by ultrasound, from vibratile eyelashes, exotoxins, endotoxins, spores, viruses, fungi or yeasts, where said pathogenic material is inactivated by EIB and formalin.nThere are three types of I-spga antigen. The standard I-spga antigen is composed of 18 to 24 antibiotic-resistant bacterial species isolated from patients in Romania. The specific I-spga antigen complex is composed of the I-spga complex antigen containing a mixture of 7-9 strains from a single species of bacteria, fungi or yeasts isolated from patients in Romania mixed with SPGA and QS -21, used for inoculation of hens previously immunized with the standard I-spga antigen. The personalized I-spga antigen is composed of pathological material derived from the patient containing cell debris and other pathogens inactivated by BEI and formalin and mixed with SPGA and QS-21 and is used to immunize hens previously immunized with antigen I -spg standard. This now patented technology creates a new generation of biological products where the immune response of hens to different groups of parenterally inoculated antigens at different time intervals overlaps. The response of the chicken is uniform and the additional administration of immunogens and SPGA as an immunopotentiator amplifies the antigenic signal and the immune response. The immunogen I-spga and the immune response contain two markers, G and A, which identify the I-spga antigen used for immunization against the antigens used to produce the Imunoinstant group bio-preparations or other similar products. The immunogen I-spga is used to immunize hens to obtain immunologically active proteins that can be used to treat immune deficiency, psoriasis, epidermolysis bullosa and other dermatitis, nosocomial infections, and resistant infections. antibiotics in the urinary system of children and adults. |
| priorityDate | 2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.